Q702 for the Treatment of Patients With Hematologic Malignancies
Status:
RECRUITING
Trial end date:
2030-09-15
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Phase:
PHASE1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Biopsy Magnetic Resonance Spectroscopy Specimen Handling